Cameron S. Gallagher
Independent ChairmanMr. Cameron S. Gallagher, also known as Cam, M.B.A., is Chairman of Crosslink Therapeutics Inc. He serves as Secretary at Ray Therapeutics, Inc. He Co-founded DioGenix, Inc. in September 2008. He is President, CEO & Director of Alessa Therapeutics, Inc. since 2024. Mr. Gallagher serves as Venture Partner at Mesa Verde Venture Partners. He had been Executive Director at Ray Therapeutics, Inc. since March 2021. He was Chief Business Officer, jCyte Inc. from 2019 until 2020. Mr. Gallagher served as Director at Zentalis Pharmaceuticals, Inc. since December 2014 until November 2024 and served as Secretary in 2015. He is Chairman of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 2020. He served as President of Zentalis Pharmaceuticals, Inc. since May 30, 2022 until November 2024 and served as its Interim CFO since April 05, 2024 until November 2024 and had served as its Interim Treasurer since April 05, 2024. He was Co-Founder of Zentalis Pharmaceuticals, Inc. and had been its Director since December 2014 until November 2024. He is Director of Helios K.K. since April 2022. He was Director of jCyte, Inc. from December 2019 to December 2020. Mr. Gallagher has served as a Director of Private Ocuphire from January 2019 until November 2020 and was its Chair since December 2019 until November 2020. Mr. Gallagher had been Vice President of Corporate Development at Oncternal Therapeutics, Inc. until 2019 and its Director from October 12, 2016 to June 2019. Mr. Gallagher served as the Chief Business Officer at Immusoft Corporation, a pre-clinical gene therapy company, a position he has held since April 2018 until 2022. Mr. Gallagher serves as the Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2009. Mr. Gallagher is acting as the Senior Vice President of Business Development for Neurelis, Inc, a privately held specialty pharmaceutical company in San Diego, California. He worked at Zavante. He serves as a Secretary and Director of Zeno Pharmaceuticals, Inc. previously, he served as the President and Chief Executive Officer of Nerveda, Inc., from September 2007 to June 2009. From December 2004 to June 2007, Mr. Gallagher served in various senior marketing positions of increasing responsibility at Verus Pharmaceuticals, Inc. He served as Vice President of Marketing for Verus Pharmaceuticals. From 1992 to 2004, Mr. Gallagher served a variety of positions within commercial operations with increasing levels of responsibility at Dura Pharmaceuticals and CV Therapeutics. He has also served on the boards of VelosBio Inc., since October 2017 until 2020 and SelectION, Inc., since June 2018. Mr. Gallagher served as the Chief Business Officer of Kalyra Pharmaceuticals, Inc. from July 2013 to January 2024. Mr. Gallagher has also served as a member of the Board of Directors of Healios K.K from March 2022 to March 2023. Mr. Gallagher has served on the Board of the Moores Cancer Center at UC San Diego Health since May 2019. Mr. Gallagher served as the Chief Business Officer and Director of RetroSense Therapeutics, LLC from 2014 to 2016 and was its Head of Corporate Development. He has been its Chairman of the Board since inception October 2008. He serves as a Director of Ark Animal Health Inc. He served as a Director of Sorrento Therapeutics, Inc. from September 6, 2012 to August 6, 2014. He was Director of Immusoft Corporation until 2026. Mr. Gallagher holds an M.B.A. from the University of San Diego in 1997 and a B.S. in Business Administration from the Ohio University in 1992.
Positions
- Company NameOpus Genetics, Inc.Stock CodeIRDPositionIndependent Chairman
